Barclays’s Repros Therapeutics Inc. RPRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q2 | – | Sell |
-6,300
| Closed | -$8K | – | 7316 |
|
|
2017
Q1 | $8K | Sell |
6,300
-1,300
| -17% | -$1.63K | ﹤0.01% | 6166 |
|
|
2016
Q4 | $10K | Sell |
7,600
-26,400
| -78% | -$45.9K | ﹤0.01% | 5920 |
|
|
2016
Q3 | $71K | Buy |
34,000
+18,000
| +113% | +$35.6K | ﹤0.01% | 4761 |
|
|
2016
Q2 | $26K | Buy |
+16,000
| New | +$30.7K | ﹤0.01% | 5178 |
|
|
2016
Q1 | – | Sell |
-25,800
| Closed | -$26K | – | 6925 |
|
|
2015
Q4 | $26K | Sell |
25,800
-6,100
| -19% | -$19.6K | ﹤0.01% | 5115 |
|
|
2015
Q3 | $223K | Buy |
31,900
+7,600
| +31% | +$58.1K | ﹤0.01% | 4069 |
|
|
2015
Q2 | $170K | Sell |
24,300
-27,200
| -53% | -$212K | ﹤0.01% | 4259 |
|
|
2015
Q1 | $412K | Sell |
51,500
-71,400
| -58% | -$639K | ﹤0.01% | 3776 |
|
|
2014
Q4 | $1.11M | Buy |
122,900
+8,400
| +7% | +$71.6K | ﹤0.01% | 3123 |
|
|
2014
Q3 | $1.03M | Buy |
114,500
+33,400
| +41% | +$495K | ﹤0.01% | 3316 |
|
|
2014
Q2 | $1.38M | Buy |
81,100
+7,000
| +9% | +$114K | ﹤0.01% | 3009 |
|
|
2014
Q1 | $1.26M | Buy |
74,100
+34,000
| +85% | +$658K | ﹤0.01% | 2992 |
|
|
2013
Q4 | $722K | Sell |
40,100
-507,800
| -93% | -$9.59M | ﹤0.01% | 3731 |
|
|
2013
Q3 | $14.2M | Buy |
547,900
+348,800
| +175% | +$7.47M | 0.02% | 891 |
|
|
2013
Q2 | $3.67M | Buy |
+199,100
| New | +$3.52M | ﹤0.01% | 1892 |
|
Barclays's RPRX Position: Q1 2018 in Review
Barclays sold out of Repros Therapeutics Inc. (RPRX) in Q1 2018, closing a stake of 124 shares.
Barclays first reported a position in RPRX in Q2 2013 and held it in 19 quarters. The position peaked at $7.87M in Q2 2013. 1 fund tracked by Wall St. Rank holds RPRX as of Q1 2018.
- Barclays reported no remaining Repros Therapeutics Inc. position as of Q1 2018 after selling out during the quarter.
- Barclays sold 124 Repros Therapeutics Inc. shares in Q1 2018.
- Barclays first reported a position in Repros Therapeutics Inc. in Q2 2013 and held it in 19 quarters.
- Barclays's Repros Therapeutics Inc. position peaked at $7.87M in Q2 2013.
- 1 fund tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q1 2018.
Based on Barclays's 13F filing for Q1 2018, filed 15 May 2018.